Rossari Biotech Limited (BOM:543213)
India
· Delayed Price · Currency is INR 695.65
+9.20 (1.34%)
At close: May 13, 2025
Rossari Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Revenue | 20,803 | 18,306 | 16,559 | 14,830 | 7,093 | Upgrade
|
| Revenue Growth (YoY) | 13.64% | 10.55% | 11.66% | 109.06% | 18.21% | Upgrade
|
| Cost of Revenue | 14,333 | 13,007 | 11,765 | 11,121 | 4,646 | Upgrade
|
| Gross Profit | 6,470 | 5,298 | 4,794 | 3,708 | 2,447 | Upgrade
|
| Selling, General & Admin | 1,323 | 1,098 | 1,039 | 726.02 | 456.35 | Upgrade
|
| Other Operating Expenses | 2,496 | 1,769 | 1,609 | 1,200 | 760.31 | Upgrade
|
| Operating Expenses | 4,490 | 3,471 | 3,277 | 2,416 | 1,445 | Upgrade
|
| Operating Income | 1,980 | 1,827 | 1,516 | 1,292 | 1,002 | Upgrade
|
| Interest Expense | -178.11 | -193.72 | -223.15 | -126.56 | -29.92 | Upgrade
|
| Interest & Investment Income | - | 22.39 | 25.21 | 49.77 | 42.7 | Upgrade
|
| Earnings From Equity Investments | 9.78 | 1.75 | 9.57 | 15.47 | 4.11 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 66.77 | 84.61 | 62.05 | 4.86 | Upgrade
|
| Other Non Operating Income (Expenses) | 40.09 | 3.59 | 5.06 | 50.8 | 17 | Upgrade
|
| EBT Excluding Unusual Items | 1,852 | 1,728 | 1,418 | 1,344 | 1,041 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 25.68 | 7.07 | 12.52 | -0.08 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 18.78 | 2.83 | 6.38 | 4.32 | Upgrade
|
| Other Unusual Items | - | 3.73 | 14.67 | - | 23.02 | Upgrade
|
| Pretax Income | 1,852 | 1,776 | 1,442 | 1,363 | 1,068 | Upgrade
|
| Income Tax Expense | 488.07 | 469.26 | 369.62 | 385.8 | 267.92 | Upgrade
|
| Earnings From Continuing Operations | 1,364 | 1,307 | 1,073 | 976.95 | 800.46 | Upgrade
|
| Minority Interest in Earnings | - | - | - | -0.21 | 1.74 | Upgrade
|
| Net Income | 1,364 | 1,307 | 1,073 | 976.74 | 802.2 | Upgrade
|
| Net Income to Common | 1,364 | 1,307 | 1,073 | 976.74 | 802.2 | Upgrade
|
| Net Income Growth | 4.35% | 21.85% | 9.81% | 21.76% | 22.94% | Upgrade
|
| Shares Outstanding (Basic) | 55 | 55 | 55 | 55 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 55 | 55 | 55 | 52 | Upgrade
|
| Shares Change (YoY) | 0.08% | -0.05% | 0.33% | 6.37% | 5.16% | Upgrade
|
| EPS (Basic) | 24.66 | 23.67 | 19.46 | 17.81 | 15.56 | Upgrade
|
| EPS (Diluted) | 24.63 | 23.62 | 19.38 | 17.70 | 15.47 | Upgrade
|
| EPS Growth | 4.28% | 21.88% | 9.49% | 14.41% | 16.93% | Upgrade
|
| Free Cash Flow | -210.69 | -880.28 | 1,187 | -88.67 | -103.17 | Upgrade
|
| Free Cash Flow Per Share | -3.81 | -15.91 | 21.44 | -1.61 | -1.99 | Upgrade
|
| Dividend Per Share | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 | Upgrade
|
| Gross Margin | 31.10% | 28.94% | 28.95% | 25.01% | 34.50% | Upgrade
|
| Operating Margin | 9.52% | 9.98% | 9.16% | 8.71% | 14.13% | Upgrade
|
| Profit Margin | 6.56% | 7.14% | 6.48% | 6.59% | 11.31% | Upgrade
|
| Free Cash Flow Margin | -1.01% | -4.81% | 7.17% | -0.60% | -1.45% | Upgrade
|
| EBITDA | 2,651 | 2,411 | 2,138 | 1,768 | 1,230 | Upgrade
|
| EBITDA Margin | 12.74% | 13.17% | 12.91% | 11.92% | 17.33% | Upgrade
|
| D&A For EBITDA | 670.73 | 583.62 | 621.4 | 476 | 227.13 | Upgrade
|
| EBIT | 1,980 | 1,827 | 1,516 | 1,292 | 1,002 | Upgrade
|
| EBIT Margin | 9.52% | 9.98% | 9.16% | 8.71% | 14.13% | Upgrade
|
| Effective Tax Rate | 26.36% | 26.42% | 25.63% | 28.31% | 25.08% | Upgrade
|
| Revenue as Reported | 20,843 | 18,380 | 16,614 | 14,950 | 7,180 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.